M. Harris
Directeur Technique/Scientifique/R&D chez ALTIMMUNE, INC.
Fortune : 386 158 $ au 30/04/2024
Profil
M.
Scott Harris was the founder of Lyric Pharmaceuticals, Inc. (founded in 2013) where he held the title of Chief Medical Officer from 2013 to 2018.
He is currently working as a Principal at Middleburg Consultants, Inc., a Professor at Georgetown University School of Medicine, and the Chief Medical Officer at Altimmune, Inc. (since 2019).
In his former positions, he served as the Chief Medical Officer & VP-Clinical Affairs at Napo Pharmaceuticals, Inc., Chief Medical Officer at Avaxia Biologics, Inc., Chief Medical Officer at OCERA Therapeutics LLC, and Chief Medical Officer at Tranzyme Pharma, Inc. (Canada).
Dr. Harris obtained a doctorate degree from Harvard Medical School, an undergraduate degree from Harvard College, and a graduate degree from the University of Wisconsin School of Medicine & Public Health.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ALTIMMUNE, INC.
0,08% | 22/03/2024 | 53 633 ( 0,08% ) | 386 158 $ | 30/04/2024 |
Postes actifs de M. Harris
| Sociétés | Poste | Début |
|---|---|---|
| ALTIMMUNE, INC. | Directeur Technique/Scientifique/R&D | 09/09/2019 |
| Middleburg Consultants, Inc. | Corporate Officer/Principal | - |
| Georgetown University School of Medicine | Corporate Officer/Principal | - |
Anciens postes connus de M. Harris
| Sociétés | Poste | Fin |
|---|---|---|
Lyric Pharmaceuticals, Inc.
 Lyric Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA. | Fondateur | 01/05/2018 |
| OCERA THERAPEUTICS INC | Directeur Technique/Scientifique/R&D | - |
Avaxia Biologics, Inc.
 Avaxia Biologics, Inc. BiotechnologyHealth Technology Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA. | Directeur Technique/Scientifique/R&D | - |
| Tranzyme Pharma, Inc. (Canada) | Directeur Technique/Scientifique/R&D | - |
Napo Pharmaceuticals, Inc.
 Napo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Napo Pharmaceuticals, Inc. provides pharmaceutical products for gastro-intestinal disorders. The company was founded by Lisa A. Conte in November 2001 and is headquartered in San Francisco, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de M. Harris
| Harvard Medical School | Doctorate Degree |
| University of Wisconsin School of Medicine & Public Health | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALTIMMUNE, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Napo Pharmaceuticals, Inc.
Napo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Napo Pharmaceuticals, Inc. provides pharmaceutical products for gastro-intestinal disorders. The company was founded by Lisa A. Conte in November 2001 and is headquartered in San Francisco, CA. | Health Technology |
Avaxia Biologics, Inc.
Avaxia Biologics, Inc. BiotechnologyHealth Technology Avaxia Biologics, Inc. operated as a clinical-stage biotechnology company. It engaged in the development of gut-targeted antibody therapeutics for gastroenterology indications. Gut-targeted antibody therapeutics is orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. The company was founded by David Poorvin and Barbara S. Fox in 2005 and was headquartered in Lexington, MA. | Health Technology |
Lyric Pharmaceuticals, Inc.
Lyric Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA. | Health Technology |
Ocera Therapeutics, Inc.
 Ocera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ocera Therapeutics, Inc. manufactures pharmaceuticals products. The company was founded in 2004 and is headquartered in Hazelwood, MO. | Health Technology |
| Tranzyme Pharma, Inc. (Canada) | |
| Middleburg Consultants, Inc. |
